Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects

Relapse limits the therapeutic efficacy both of chimeric antigen receptor (CAR) T cells and allogeneic hematopoietic cell transplantation (allo-HCT). Patients may undergo these therapies sequentially to prevent or treat relapsed malignancy. However, direct integration of the 2 therapies has been avo...

Descripción completa

Detalles Bibliográficos
Autores principales: Patterson, Michael T., Khan, Shanzay M., Nunes, Natalia S., Fletcher, Rochelle E., Bian, Jing, Hadjis, Ashley D., Eckhaus, Michael A., Mendu, Suresh K., de Paula Pohl, Alessandra, Venzon, David J., Choo-Wosoba, Hyoyoung, Ishii, Kazusa, Qin, Haiying, Fry, Terry J., Cam, Maggie, Kanakry, Christopher G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979711/
https://www.ncbi.nlm.nih.gov/pubmed/36201744
http://dx.doi.org/10.1182/blood.2022016660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979711/
https://www.ncbi.nlm.nih.gov/pubmed/36201744
http://dx.doi.org/10.1182/blood.2022016660

Ejemplares similares